Press Releases

Date Title and Summary Additional Formats  
Toggle Summary Karyopharm Announces Outcome of FDA Advisory Committee Meeting Reviewing Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma
NEWTON, Mass. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) met to discuss the New Drug Application (NDA) for
View HTML
Toggle Summary Karyopharm Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three Prior Therapies
NEWTON, Mass. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that NASDAQ has halting trading of the Company’s common stock. The U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC)
View HTML
Toggle Summary Karyopharm Strengthens Management Team with Appointment of Michael P. Mason as Chief Financial Officer
-- Formerly of Alnylam Pharmaceuticals , Praecis Pharmaceuticals , and KPMG; Brings Over 18 Years of Financial Leadership Experience Within the Life Sciences Industry -- NEWTON, Mass. , Feb. 25, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical
View HTML
Toggle Summary Karyopharm to Report Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019
Conference Call Scheduled for Thursday, February 28, 2019 at 8:30 a.m. ET NEWTON, Mass. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report fourth quarter and full year 2018 financial results on
View HTML
Toggle Summary Karyopharm Announces FDA Advisory Committee Meeting to Review Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three Prior Therapies
NEWTON, Mass. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) is scheduled to review data supporting the
View HTML
Toggle Summary Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass. , Feb. 04, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 428,500 shares of Karyopharm’s
View HTML
Toggle Summary Karyopharm Announces Submission of Marketing Authorization Application to the European Medicines Agency for Selinexor for the Treatment of Patients with Penta-Refractory Multiple Myeloma
-- Selinexor Marketing Authorization Application to be Reviewed Under Accelerated Assessment -- NEWTON, Mass. , Jan. 08, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has submitted a Marketing Authorization
View HTML
Toggle Summary Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 78,000 shares of Karyopharm’s
View HTML
Toggle Summary Karyopharm to Present at the 37th Annual J.P. Morgan Healthcare Conference
NEWTON, Mass. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman , MD, PhD, Chief Executive Officer, will present at the 37 th Annual J.P. Morgan Healthcare Conference on Monday, January 7,
View HTML
Toggle Summary Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass. , Dec. 04, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 180,500 shares of Karyopharm’s
View HTML